[go: up one dir, main page]

Bast, 2005 - Google Patents

FOCIS abstract supplement

Bast, 2005

View HTML
Document ID
8531670311409051772
Author
Bast G
Publication year
Publication venue
Clinical Immunology (Orlando, Fla.)

External Links

Snippet

Methodology Plants were analysed after 15 days of germination, the contents of chlorophyll a, b carbohyderates, proteins and amino acids were determiend by standered method (Chapman. SB, 1976). Mineral ions were analysed by flame photometry and atomic …
Continue reading at pmc.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
Price et al. The role of dendritic cell subsets and innate immunity in the pathogenesis of type 1 diabetes and other autoimmune diseases
Gorczynski CD200: CD200R‐mediated regulation of immunity
Krovi et al. Activation pathways that drive CD4+ T cells to break tolerance in autoimmune diseases
ES2983677T3 (en) Method for determining the toxicity of an immunomodulatory drug for use in humans
Asavaroengchai et al. An essential role for IFN-γ in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation
JPH08500083A (en) Suppression of T-cell proliferation using peptide fragments of myelin basic protein
WO2012011113A2 (en) Regulatory immune cells with enhanced targeted cell death effect
Bast FOCIS abstract supplement
Clemente Casares pMHC-class II nanovaccine to treat autoimmune diseases
Khosravi-Maharlooei et al. Follicular helper-and peripheral helper-like T cells drive autoimmune disease in human immune system mice
Badal et al. Microbiome and Cellular Players in Type 1 Diabetes: From Pathogenesis to Protection
Ihantola T-cell dysfunction and autoantigen recognition in type 1 diabetes
Cobb et al. Mechanism of Action of Oral Salmonella-Based Vaccine to Prevent and Reverse Type 1
Wildberger Therapeutic approach for Myasthenia Gravis using conditioned mesenchymal stromal cells
US20210048429A1 (en) Plzf+ regulatory cd8 t cells for control of inflammation
Chang X-linked FoxP3 and OTC in immune tolerance and autoimmunity
JP2024527074A (en) Selective tolerization - Methods for selectively generating tolerogenic dendritic cells
Rasché Processing and presentation of glutamic acid decarboxylase 65 T cell-inducing epitopes: implications in the non-obese diabetic mouse model of type 1 diabetes
Gaignage et al. " TLR7 activation by LDV/R848 (Resiquimod) prevents acute graft versus host disease and cooperates with anti-IL-27 antibody for optimal protection
Rivollier et al. Retinoic acid modulates the early expansion and differentiation of CD4 (+) T cells during the development of intestinal inflammation
Sang Novel Humanized Mice to Test Therapeutics for Human Type L Diabetes
Scott Mechanisms and inhibition of CD4+ T cell migration in pre-clinical and humanised mouse models of type 1 diabetes
Van der Touw Signaling through C3a and C5a receptors diminishes regulatory T cell function and stability
Picard et al. Regulatory role of B cell-derived transforming growth factor-β1 expression in autoimmune neuroinflammation
Jones The immunobiology of graft-versus-host disease across a minor histocompatibility antigen barrier